ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
16:50 EST 10 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and antibody expertise, today
announced the presentation of new clinical d...
Other Sources for this Article
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
More From BioPortfolio on "ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
